Education 【 display / non-display 】

Education 【 display / non-display 】

• 2011

  -

  2019

  Sapporo Medical University   Graduate School of Medicine  

• 2002

  -

  2008

  Sapporo Medical University   医学部   医学科  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 2019.03   Sapporo Medical University   Doctor of Medicine

Research Experience 【 display / non-display 】

Research Experience 【 display / non-display 】

• 2023.04

  -

  Now

  Sapporo Medical University   放射線医学講座   助教

• 2020.01

  -

  2023.03

  手稲渓仁会病院   放射線治療科   主任医長

• 2020.01

  -

  2023.03

  Sapporo Medical University   放射線医学講座   研究員

• 2019.04

  -

  2019.12

  Sapporo Medical University   放射線医学講座   助教

• 2015.10

  -

  2016.09

  Sapporo Medical University   放射線医学講座   特任助教

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 2011.02

  -

  Now

  日本放射線腫瘍学会

• 2010.07

  -

  Now

  日本医学放射線学会

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Radiology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   放射線医学講座   助教  

Research Interests 【 display / non-display 】

Research Interests 【 display / non-display 】

• DNA損傷修復

• 放射線腫瘍学

• リキッドバイオプシー

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy.

  Mio Kitagawa, Masanori Someya, Tomokazu Hasegawa, Toshihiko Mikami, Kazuaki Asaishi, Tadashi Hasegawa, Yoshihisa Matsumoto, Goro Kutomi, Ichiro Takemasa, Koh-Ichi Sakata

  Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   195 ( 7 ) 648 - 658  2019.07  [Refereed]  [International journal]

  Authorship：   Lead author

  　View Summary

  BACKGROUND: We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP). PATIENTS AND METHODS: The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens. RESULTS: The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP. CONCLUSION: IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.

  DOI PubMed

• Prediction of late adverse events in pelvic cancer patients receiving definitive radiotherapy using radiation-induced gamma-H2AX foci assay.

  Masanori Someya, Tomokazu Hasegawa, Asako J Nakamura, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Sho Mafune, Yutaro Ikeuchi, Hiroshi Tauchi, Koh-Ichi Sakata

  Journal of radiation research   64 ( 6 ) 948 - 953  2023.11  [International journal]

  　View Summary

  Radiation can induce DNA double-stranded breaks, which are typically detected by the fluorescence of phosphorylated histone H2AX. In this study, we examined the usefulness of the dynamics of radiation-induced gamma-H2AX foci of peripheral blood lymphocytes (PBLs), as a marker of DNA repair ability, in predicting late adverse events from radiotherapy. A total of 46 patients with cervical, vaginal and anal canal cancers treated with radical radiotherapy between 2014 and 2019 were included in this analysis. Concurrent chemotherapy was administered in 36 cases (78.3%). Peripheral blood was obtained before treatment, and then irradiated ex vivo with 1 Gy X-ray. The ratio of radiation-induced gamma-H2AX foci in PBLs measured at 30 min and at 4 h was defined as the foci decay ratio (FDR). With a median follow-up of 54 months, 9 patients (19.6%) were observed to have late genitourinary or gastrointestinal (GU/GI) toxicity. The FDR ranged from 0.51 to 0.74 (median 0.59), with a significantly higher incidence of Grade 1 or higher late adverse events in the FDR ≥ 0.59 group. In multivariate analysis, FDR ≥ 0.59 and hypertension also emerged as significant factors associated with the development of late toxicities. Overall, our results suggest that measurement of radiation-induced gamma-H2AX foci in PBLs may predict the risk of late GU/GI toxicities from chemoradiotherapy, which can enable tailoring the radiation dose to minimize adverse effects.

  DOI PubMed

• 化学放射線+免疫療法を行った3期NSCLCにおける、末梢血リンパ細胞のTCRレパトア解析

  染谷 正則, 長谷川 智一, 北川 未央, 土屋 高旭, 後町 俊夫, 眞船 翔, 金関 貴幸, 蒔田 芹奈, 鳥越 俊彦, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   O46 - 3  2023.10

• Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.

  Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki, Koh-Ichi Sakata

  Medical molecular morphology    2023.07  [Domestic journal]

  　View Summary

  Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000-2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells (P = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 (P = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells (P = 0.009 and P = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.

  DOI PubMed

• Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer.

  Masanori Someya, Serina Tokita, Takayuki Kanaseki, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yoh Kozuka, Shoh Mafune, Yutaro Ikeuchi, Mamoru Takahashi, Keigo Moniwa, Kazuhiko Matsuo, Tadashi Hasegawa, Toshihiko Torigoe, Koh-Ichi Sakata

  Cancer science   113 ( 12 ) 4394 - 4400  2022.12  [International journal]

  　View Summary

  Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation therapy has improved the overall survival of patients with NSCLC, the synergistic action mechanisms of CRT and immunotherapy on T cells remain unclear. In addition, there is a paucity of reliable biomarkers to predict clinical responses to therapy. In this study, we analyzed T-cell receptor (TCR) sequences in the peripheral blood of five patients with NSCLC. T-cell receptor analysis was undertaken before treatment, after CRT, and after PD-L1 blockade. Notably, we observed the expansion and alteration of the dominant T-cell clonotypes in all cases with a complete response. In contrast, neither expansion nor alteration of the TCR repertoire was observed in cases with progressive disease. T cell expansion was initiated after CRT and was further enhanced after PD-L1 blockade. Our findings suggest the systemic effect of CRT on circulating T cells in addition to the curative effect on limited tumor sites. Dynamic changes in circulating T-cell clonotypes could have a prognostic significance for combined CRT and PD-L1 blockade.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• 化学放射線療法+免疫療法を行った3期切除不能非小細胞肺癌における,末梢血リンパ細胞のTCRレパトア解析

  染谷正則, 長谷川智一, 北川未央, 土屋高旭, 眞船翔, 後町俊夫, 池内佑太郎, 金関貴幸, 鳥越俊彦, 坂田耕一

  日本免疫治療学会学術集会プログラム・抄録集   20th  2023

  J-GLOBAL

• Transmanubrial osteomuscular sparing approachによる腕頭動脈・気管側壁合併切除により切除し得た食道癌術後106recR再発の2例

  岡田 尚也, 西原 聖仁, 佐藤 綾, 北川 未央, 田中 一成, 山吹 匠, 三浦 勝利, 石黒 敦, 加藤 健太郎, 木ノ下 義宏

  日本食道学会学術集会プログラム・抄録集 ( (NPO)日本食道学会 )  76回   170 - 170  2022.09

• 血中エクソソームmiRNAを用いた子宮頸癌の治療効果予測

  染谷正則, 土屋高旭, 福島悠希, 池内佑太郎, 眞船翔, 小塚陽, 北川未央, 後町俊夫, 坂田耕一

  日本免疫治療学会学術集会プログラム・抄録集   19th  2022

  J-GLOBAL

• 子宮頸癌根治照射症例におけるCD8の浸潤形式と予後との関連

  染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

  日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  59回   O37 - 7  2021.10

• 75歳以上高齢食道癌患者における食道癌手術周術期リスク因子の検討

  岡田 尚也, 西原 聖仁, 佐藤 綾, 市丸 千聖, 北川 未央, 山吹 匠, 三浦 勝利, 石黒 敦, 加藤 健太郎, 木ノ下 義宏

  日本食道学会学術集会プログラム・抄録集 ( (NPO)日本食道学会 )  75回   195 - 195  2021.09

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• リキッドバイオプシーを用いた肺癌放射線治療効果および有害事象発症の予測

  若手研究

  Project Year :

  2023.04

  -

  2026.03

   

  北川 未央

• リキッドバイオプシーを用いた肺癌個別化放射線治療の検討

  若手研究

  Project Year :

  2019.04

  -

  2023.03

   

  北川 未央

  　View Summary

  本研究は、化学放射線治療を行う原発性肺癌患者に対して、DNA損傷修復や免疫チェックポイントに関連するタンパク発現を免疫組織染色によって調べ、末梢血リンパ球や血中に含まれるエクソソーム（細胞外小胞）に内包されるmRNAおよびmicroRNAの発現を解析し、放射線治療効果や放射線性肺障害を予測するバイオマーカー探索を行うことを目的としている。 2020年度は、肺癌化学放射線治療後に抗PD-L1抗体であるデュルバルマブ投与を行う7名の患者より、照射前、照射後に血液を採取し、血漿およびリンパ球などの試料を分離採取した。また、生検検体におけるDNA損傷修復タンパクおよび免疫チェックポイントに関わるタンパク発現の免疫組織染色解析や、対象患者の進行度等の臨床因子やDose Volume Histogram上で算出される肺V20やV5、Mean Lung Doseなどのパラメータと放射線治療効果、放射線肺障害との関連性についての解析を進めた。 これまで我々のグループでは、免疫組織染色を用いて腫瘍組織におけるDNA損傷修復に関わるタンパク発現と放射線治療効果の関係について研究しており、また、免疫チェックポイントに関わるタンパク発現と放射線治療効果についても報告している。これらのタンパク発現および血中の腫瘍由来エクソソーム内のmRNA/miRNA発現解析を組み合わせることによってで、独自性高くかつ簡便なバイオマーカーの探索が可能であり、肺癌に対する個別化放射線治療の実現を目指すことが可能と考えられる。

• Development of a practical radiosensitivity prediction method for clinical applications

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2018.04

  -

  2021.03

   

  Sakata Koh-ichi

  　View Summary

  Using biopsy and surgical specimens of breast and cervical cancers, we analyzed the correlation between various protein expressions and radiotherapy outcomes. Radiotherapy of cervical cancer increased the expression of PD-L1 in tumor cells, and there was a strong correlation between the expression of PD-L1 in tumor cells after radiotherapy and overall survival. This suggests that irradiation-induced immunological changes may affect the radiotherapy effect. In patients with early-stage breast cancer treated with postoperative radiotherapy, XRCC4 expression rates in tumor cells were significantly correlated with intra-breast recurrence. By type of recurrence, there was a correlation with XRCC4 expression in True recurrence. True recurrence may be due to the low radiosensitivity of tumor cells.

• Development of methods predicting radiosensitivity that can be clinically applied

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2015.04

  -

  2018.03

   

  Sakata Koh-ichi

  　View Summary

  We developed a practical method for predicting radiosensitivity to realize individualized radiotherapy according to the biological characteristics of cancer cells. In uterine cervical cancer and prostate cancer, the correlation between expression proteins involved in repair of DNA double-strand breaks of tumor cells by biopsy specimens and radiotherapy results is analyzed, which is a predictive factor of therapeutic effect. In uterine cervical cancer, the expression rates of Ku 86 and XRCC 4 were predictors of the radiotherapeutic effect on cervical cancer. In prostate cancer, the expression of Ku70 in prostate cancer cells is a prognostic factor independent of clinical factors, and it has been shown that in addition to the prognostic factors presently used in clinical practice, recurrence after radiation treatment can be predicted with high accuracy.